This oversubscribed round was led by prominent European venture capital firms HV Capital and Unbound. With a current valuation of $75 million, Bioniq plans to leverage the new funds to expand its global market presence, particularly focusing on the dietary supplements sector. The company aims to enhance product development, integrate a global laboratory network, and expand its market, operations, and human resources in the US and Middle East. Additionally, Bioniq will implement a corporate platform tailored for medical, wellness, and athletic institutions.

Bioniq has experienced substantial growth over the past year, driven by its data-driven, personalised solutions. The US market has been particularly significant, now accounting for over 50% of its customer base and experiencing regional growth rates exceeding 500% in the last two quarters. Bioniq's ability to provide quantifiable before-and-after snapshots of users’ nutrient needs and optimisation progress has made it a preferred partner for leading health and sports institutions such as Lanserhof and UFC. The brand is also trusted by top athletes, including Manchester United’s Diogo Dalot and former NBA All-Star Andrei Kirilenko, who rely on Bioniq to optimise their micronutrient levels and enhance performance and recovery.

"We've entered a new era in nutritional supplementation over the last six years, where it’s become clear that one-size-fits-all solutions are simply inefficient,” said Vadim Fedotov, Co-Founder and CEO of Bioniq. “Everyone's health journey is unique and fluid. Customers need advanced, adaptable products that provide evolving support for personal health goals. Our AI-driven approach and extensive biochemical database allow us to create customised supplements that provide quantifiable results and cater to individuals’ specific needs. Beyond meeting consumer demand, we’re setting a new standard in the industry by making the process and results transparent to the users."

Two tailored solutions for health optimisation

Over the past decade, Bioniq has developed the largest proprietary biochemical database of its kind, leveraging blood test data from customers across five continents. The AI-powered, patent-pending Bioniq algorithm assesses an individual’s height, weight, age, lifestyle, and health goals to identify micronutrient imbalances and create customised supplement formulas for health optimisation.

Bioniq PRO: This service offers high performers and health enthusiasts the highest level of personalisation. By incorporating blood biomarker data, users can upload existing bloodwork into the system for recommendations based on a global repository of data or book a blood test through Bioniq’s partner labs. The analysed data identifies current nutrient statuses and imbalances, providing a tailor-made daily supplement formula. Users also have access to 1:1 nutrition consultations with a Registered Dietitian to discuss their unique needs and next steps.

Bioniq GO: This option provides a more accessible approach, utilising the same proprietary database. Users complete a questionnaire that prompts the AI algorithm to recommend a unique supplement blend based on their responses and previous users’ blood biomarker data.

All of Bioniq’s supplements are Swiss-made, pharmaceutical-grade, and utilise precise micro-dosing to address individual needs and deficiencies. Each formula includes a unique mix of antioxidants, vitamins, minerals, phytonutrients, amino acids, and prebiotic fibre, delivered in patented prebiotic guar granules. These granules mimic the body’s natural digestion process, minimising nutrient competition and maximising bioavailability.

"Bioniq's exceptional growth is a testament to its innovative approach for high quality personalised health solutions that professional athletes across the world rely on,” said David Kuczek, General Partner at HV Capital. “With sales from across 60 countries with the majority coming from North America, the most important market for health solutions globally, Bioniq is well-positioned to continue its trajectory of rapid expansion."

"Bioniq's innovative approach to nutrition is based on the idea that everyone has different nutritional needs and deficiencies, and that generic multivitamins are not enough to address them. We are impressed by Bioniq's vision and technology, and we believe that they are disrupting the supplement industry with their personalised and science-based approach. We are excited to support them as they grow and scale their business," said Shravin Mittal, CEO of Unbound.